North America Pharmaceutical Contract Manufacturing 麻豆原创 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity

Publication ID:

GRM1020040

Publication Date:

October 26, 2020

Pages:

110

Publisher:

Grace 麻豆原创 Data

Countries:

North America [1]

USD 3,000.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

North America pharmaceutical contract manufacturing market is expected to grow by 5.4% annually in the forecast period and reach $62.8 billion by 2030 driven by rising need for medicines amid COVID-19 pandemic and increasing dependence on contract manufacturing organizations due to improved efficiency and productivity.
Highlighted with 28 tables and 49 figures, this 110-page report 鈥淣orth America Pharmaceutical Contract Manufacturing 麻豆原创 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire North America pharmaceutical contract manufacturing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical contract manufacturing market in every aspect of the classification from perspectives of Category, Product, Phase, Type, Therapeutic Application, and Country.

Based on Category, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Pharmaceutical Industry
鈥� Biopharmaceutical Industry

Based on Product, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Active Pharmaceutical Ingredients (API)
鈥� Branded API Manufacturing
鈥� Generic API Manufacturing
Finished Dosage Formulations (FDF)
鈥� Solid Dosage
鈥� Oral Liquids
鈥� Parenteral/Injectables
鈥� Other FDFs
Secondary Packaging

Based on Phase, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Clinical Manufacturing
鈥� Commercial Manufacturing

Based on Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Sterile Products
鈥� Non-Sterile Products

Based on Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Infectious Diseases
鈥� Oncology
鈥� Metabolic Disorders
鈥� Cardiovascular Disorders
鈥� Central Nervous System
鈥� Pulmonary Disorders
鈥� Gastrointestinal Disorders
鈥� Other Therapeutic Applications

Geographically, the following national/local markets are fully investigated:
鈥� U.S.
鈥� Canada
鈥� Mexico
For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Phase, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America pharmaceutical contract manufacturing market are assayed quantitatively and qualitatively through GMD鈥檚 Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

Table of Contents
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of 麻豆原创 Research Methodology 11
1.2.2 麻豆原创 Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 麻豆原创 Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 麻豆原创 Overview and Dynamics 20
2.1 麻豆原创 Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the 麻豆原创 24
2.2 Major Growth Drivers 26
2.3 麻豆原创 Restraints and Challenges 29
2.4 Emerging Opportunities and 麻豆原创 Trends 32
2.5 Porter鈥檚 Fiver Forces Analysis 36
3 Segmentation of North America 麻豆原创 by Category 41
3.1 麻豆原创 Overview by Category 41
3.2 Pharmaceutical Industry 43
3.3 Biopharmaceutical Industry 44
4 Segmentation of North America 麻豆原创 by Product 45
4.1 麻豆原创 Overview by Product 45
4.2 Active Pharmaceutical Ingredients (API) 47
4.2.1 Branded API Manufacturing 48
4.2.2 Generic API Manufacturing 49
4.3 Finished Dosage Formulations (FDF) 50
4.3.1 Solid Dosage 52
4.3.2 Oral Liquids 53
4.3.3 Parenteral/Injectables 54
4.3.4 Other FDFs 55
4.4 Secondary Packaging 56
5 Segmentation of North America 麻豆原创 by Phase 57
5.1 麻豆原创 Overview by Phase 57
5.2 Clinical Manufacturing 59
5.3 Commercial Manufacturing 60
6 Segmentation of North America 麻豆原创 by Type 61
6.1 麻豆原创 Overview by Type 61
6.2 Sterile Products 63
6.3 Non-Sterile Products 64
7 Segmentation of North America 麻豆原创 by Therapeutic Application 65
7.1 麻豆原创 Overview by Therapeutic Application 65
7.2 Infectious Diseases 67
7.3 Oncology 68
7.4 Metabolic Disorders 69
7.5 Cardiovascular Disorders 70
7.6 Central Nervous System 71
7.7 Pulmonary Disorders 72
7.8 Gastrointestinal Disorders 73
7.9 Other Therapeutic Applications 74
8 North America 麻豆原创 2019-2030 by Country 75
8.1 Overview of North America 麻豆原创 75
8.2 U.S. 78
8.3 Canada 82
8.4 Mexico 84
9 Competitive Landscape 86
9.1 Overview of Key Vendors 86
9.2 New Product Launch, Partnership, Investment, and M&A 90
9.3 Company Profiles 91
Aenova Group 91
Baxter BioPharma Solutions 93
Boehringer Ingelheim 94
Catalent Inc. 95
Famar S.A. 96
Hospira, Inc. 97
Jubilant Life Sciences Ltd. 98
Lonza Group 99
Patheon Inc. 100
Pfizer CentreSource 101
Recipharm AB 102
Vetter Pharma International GmbH 103
10 Investing in North America 麻豆原创: Risk Assessment and Management 104
10.1 Risk Evaluation of North America 麻豆原创 104
10.2 Critical Success Factors (CSFs) 107
Related Reports and Products 110

Companies Mentioned:

Key Players (this may not be a complete list and extra companies can be added upon request):
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.